

John A Kanis

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3894020/publications.pdf](https://exaly.com/author-pdf/3894020/publications.pdf)

Version: 2024-02-01

691
papers

101,019
citations

256

139
h-index

230

298
g-index

755
all docs

755
docs citations

755
times ranked

51447
citing authors

#	ARTICLE	IF	CITATIONS
1	An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2024, 47, 501-511.	3.5	17
2	A meta-analysis of previous falls and subsequent fracture risk in cohort studies. <i>Osteoporosis International</i> , 2024, 35, 469-494.	3.3	5
3	Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts. <i>Aging Clinical and Experimental Research</i> , 2024, 36, .	3.0	0
4	The application of FRAX in Ecuador. <i>Revista Colombiana De ReumatologÃa</i> , 2023, 30, 199-206.	0.1	2
5	The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. <i>Osteoporosis International</i> , 2023, 34, 1-9.	3.3	20
6	Adjusting conventional FRAX estimates of fracture probability according to the number of prior falls in the preceding year. <i>Osteoporosis International</i> , 2023, 34, 479-487.	3.3	12
7	Primary hyperparathyroidism and fracture probability. <i>Osteoporosis International</i> , 2023, 34, 489-499.	3.3	7
8	A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis. <i>Osteoporosis International</i> , 2023, 34, 429-447.	3.3	7
9	Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Osteoporosis International</i> , 2023, 34, 1283-1299.	3.3	3
10	Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. <i>Osteoporosis International</i> , 2023, 34, 2027-2045.	3.3	10
11	Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusCUROS). <i>Osteoporosis International</i> , 2022, 33, 67-75.	3.3	5
12	FRAX-based intervention thresholds for Pakistan. <i>Osteoporosis International</i> , 2022, 33, 105-112.	3.3	1
13	One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. <i>Osteoporosis International</i> , 2022, 33, 185-194.	3.3	11
14	Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM). <i>Osteoporosis International</i> , 2022, 33, 57-66.	3.3	11
15	Costs of patient management over 18 months following a hip, clinical vertebral, distal forearm, or proximal humerus fragility fracture in France results from the ICUROS study. <i>Osteoporosis International</i> , 2022, 33, 625-635.	3.3	6
16	Osteoporosis in Europe: a compendium of country-specific reports. <i>Archives of Osteoporosis</i> , 2022, 17, 23.	2.6	94
17	The global approach to rehabilitation following an osteoporotic fragility fracture: A review of the rehabilitation working group of the International Osteoporosis Foundation (IOF) committee of scientific advisors. <i>Osteoporosis International</i> , 2022, 33, 527-540.	3.3	32
18	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1311-1321.	4.7	22

#	ARTICLE	IF	CITATIONS
19	FRAX. , 2022, , 89-99.		1
20	FREM predicts 10-year incident fracture risk independent of FRAX [®] probability: a registry-based cohort study. Osteoporosis International, 2022, , 1.	3.3	2
21	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	3.0	48
22	Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporosis International, 2022, 33, 1185-1189.	3.3	8
23	Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Archives of Osteoporosis, 2022, 17, 49.	2.6	8
24	Prevalence of healthy aging among community dwelling adults age 70 and older from five European countries. BMC Geriatrics, 2022, 22, 174.	2.8	13
25	Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Archives of Osteoporosis, 2022, 17, 56.	2.6	9
26	Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporosis International, 2022, 33, 1725-1738.	3.3	19
27	Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH. BMJ Open, 2022, 12, e051881.	2.1	12
28	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology, 2022, 18, 366-384.	9.7	55
29	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.3	49
30	Trabecular Bone Score Adjustment for the Fracture Risk Assessment Tool (FRAX [®]). Calcified Tissue International, 2022, 111, 226-227.	3.2	3
31	Bone Turnover Marker Profiling and Fracture Risk in Older Women: Fracture Risk from Age 75 to 90. Calcified Tissue International, 2022, 111, 288-299.	3.2	8
32	A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Osteoporosis International, 2022, 33, 1895-1907.	3.3	7
33	Population screening for fracture risk in postmenopausal women – a logical step in reducing the osteoporotic fracture burden?. Osteoporosis International, 2022, 33, 1631-1637.	3.3	5
34	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 2022, 17, .	2.6	19
35	Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability – results from the Women’s Health Initiative hormone therapy trials. Osteoporosis International, 2022, 33, 2297-2305.	3.3	12
36	An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS). Archives of Osteoporosis, 2022, 17, .	2.6	2

#	ARTICLE	IF	CITATIONS
37	Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures. <i>Osteoporosis International</i> , 2022, 33, 2507-2515.	3.3	4
38	Intervention thresholds and diagnostic thresholds in the management of osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 3155-3157.	3.0	8
39	Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. <i>Osteoporosis International</i> , 2021, 32, 165-171.	3.3	6
40	Fracture risk assessment in celiac disease: a registry-based cohort study. <i>Osteoporosis International</i> , 2021, 32, 93-99.	3.3	15
41	Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. <i>Osteoporosis International</i> , 2021, 32, 39-46.	3.3	28
42	The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. <i>Osteoporosis International</i> , 2021, 32, 75-84.	3.3	31
43	Health service use pathways associated with recovery of quality of life at 12-months for individual fracture sites: Analyses of the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS). <i>Bone</i> , 2021, 144, 115805.	3.1	16
44	The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. <i>Osteoporosis International</i> , 2021, 32, 47-54.	3.3	24
45	Clodronate. <i>Bone</i> , 2021, 143, 115715.	3.1	15
46	Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. <i>Osteoporosis International</i> , 2021, 32, 113-122.	3.3	18
47	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. <i>Contemporary Clinical Trials</i> , 2021, 100, 106124.	1.9	30
48	A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. <i>Osteoporosis International</i> , 2021, 32, 1301-1311.	3.3	10
49	Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. <i>Osteoporosis International</i> , 2021, 32, 585-594.	3.3	28
50	In memory of Harry K Genant. <i>Osteoporosis International</i> , 2021, 32, 607-608.	3.3	0
51	A surrogate FRAX model for Pakistan. <i>Archives of Osteoporosis</i> , 2021, 16, 34.	2.6	5
52	Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. <i>Osteoporosis International</i> , 2021, 32, 1601-1608.	3.3	17
53	Epidemiology of hip fracture in Botswana. <i>Archives of Osteoporosis</i> , 2021, 16, 24.	2.6	14
54	The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. <i>Osteoporosis International</i> , 2021, 32, 1547-1555.	3.3	30

#	ARTICLE	IF	CITATIONS
55	Summary of the draft federal clinical guidelines for osteoporosis. Osteoporosis and Bone Diseases, 2021, 23, 4-21.	1.5	14
56	Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Medicine, 2021, 13, 16.	8.6	42
57	A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ÅY-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcified Tissue International, 2021, 108, 785-797.	3.2	11
58	FRAX-based fracture probabilities in South Africa. Archives of Osteoporosis, 2021, 16, 51.	2.6	11
59	Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporosis International, 2021, 32, 1973-1979.	3.3	7
60	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and İ ² -CTX in blood. Clinica Chimica Acta, 2021, 515, 16-20.	1.6	35
61	Short time horizons for fracture prediction tools: time for a rethink. Osteoporosis International, 2021, 32, 1019-1025.	3.3	17
62	An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporosis International, 2021, 32, 1951-1960.	3.3	42
63	FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. Journal of Osteoporosis, 2021, 2021, 1-7.	0.5	2
64	FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 2021, 16, 87.	2.6	13
65	SCOPE 2021: a new scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2021, 16, 82.	2.6	305
66	A country-specific FRAX model for Botswana. Archives of Osteoporosis, 2021, 16, 90.	2.6	5
67	Ukrainian FRAX version in the male osteoporosis management. BolĖ1, Sustavy, PozvonoĖnik, 2021, 11, 53-61.	0.1	3
68	Calibration of FRAX: A Journey, not a Destination. Calcified Tissue International, 2021, 109, 597-599.	3.2	5
69	Recovery of quality of life is associated with lower mortality 5-year post-fracture: the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS). Archives of Osteoporosis, 2021, 16, 112.	2.6	7
70	Fracture Risk Assessment and How to Implement a Fracture Liaison Service. Practical Issues in Geriatrics, 2021, , 241-256.	0.0	9
71	The application of FRAX in Saudi Arabia. Archives of Osteoporosis, 2021, 16, 166.	2.6	8
72	Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases, 2021, 24, 4-47.	1.5	54

#	ARTICLE	IF	CITATIONS
73	Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. <i>Osteoporosis International</i> , 2020, 31, 67-75.	3.3	27
74	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. <i>Osteoporosis International</i> , 2020, 31, 1-12.	3.3	240
75	Reassessment Intervals for Transition From Low to High Fracture Risk Among Adults Older Than 50 Years. <i>JAMA Network Open</i> , 2020, 3, e1918954.	6.1	7
76	Risk for hip fracture before and after total knee replacement in Sweden. <i>Osteoporosis International</i> , 2020, 31, 887-895.	3.3	5
77	Incidence of myocardial infarction and associated mortality varies by latitude and season: findings from a Swedish Registry Study. <i>Journal of Public Health</i> , 2020, 42, e440-e448.	2.0	2
78	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. <i>Bone Reports</i> , 2020, 13, 100729.	0.8	15
79	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. <i>Drugs</i> , 2020, 80, 1537-1552.	11.2	43
80	Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. <i>Archives of Osteoporosis</i> , 2020, 15, 119.	2.6	7
81	Use of age-dependent FRAX-based intervention thresholds for Singapore. <i>Archives of Osteoporosis</i> , 2020, 15, 104.	2.6	15
82	FRAX and ethnicity. <i>Osteoporosis International</i> , 2020, 31, 2063-2067.	3.3	17
83	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	7.1	206
84	Bone densitometry worldwide: a global survey by the ISCD and IOF. <i>Osteoporosis International</i> , 2020, 31, 1779-1786.	3.3	36
85	Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. <i>Osteoporosis International</i> , 2020, 31, 1059-1067.	3.3	60
86	Increased risk for hip fracture after death of a spouse—further support for bereavement frailty?. <i>Osteoporosis International</i> , 2020, 31, 485-492.	3.3	5
87	Alternative and complementary therapies in osteoarthritis and cartilage repair. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 547-560.	3.0	72
88	Quality of life after fragility fracture in the Russian Federation: results from the Russian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (ICUROS). <i>Archives of Osteoporosis</i> , 2020, 15, 37.	2.6	11
89	Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. <i>Osteoporosis International</i> , 2020, 31, 1817-1828.	3.3	58
90	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. <i>Osteoporosis International</i> , 2020, 31, 2271-2286.	3.3	89

#	ARTICLE	IF	CITATIONS
91	A surrogate FRAX model for the Kyrgyz Republic. Archives of Osteoporosis, 2020, 15, 68.	2.6	6
92	Loss in DXA-estimated total body lean mass but not fat mass predicts incident major osteoporotic fracture and hip fracture independently from FRAX: a registry-based cohort study. Archives of Osteoporosis, 2020, 15, 96.	2.6	18
93	Epidemiology of osteoporotic fracture in Kazakhstan and development of a country specific FRAX model. Archives of Osteoporosis, 2020, 15, 30.	2.6	23
94	Estimation of Long-term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. JBMR Plus, 2020, 4, e10348.	2.3	3
95	Epidemiology of hip fractures in Bulgaria: development of a country-specific FRAX model. Archives of Osteoporosis, 2020, 15, 28.	2.6	4
96	A decade of FRAX: how has it changed the management of osteoporosis?. Aging Clinical and Experimental Research, 2020, 32, 187-196.	3.0	93
97	Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporosis International, 2020, 31, 457-464.	3.3	5
98	Harmonization of commercial assays for PINP; the way forward. Osteoporosis International, 2020, 31, 409-412.	3.3	13
99	Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporosis International, 2020, 31, 1499-1506.	3.3	19
100	Screening for high fracture risk. Osteoporosis International, 2020, 31, 1179-1180.	3.3	1
101	Fragility fractures in Europe: burden, management and opportunities. Archives of Osteoporosis, 2020, 15, 59.	2.6	433
102	Sarcopenia Definitions as Predictors of Fracture Risk Independent of FRAX®, Falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A Meta-Analysis. Journal of Bone and Mineral Research, 2020, 36, 1235-1244.	3.1	37
103	Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). Journal of Bone and Mineral Research, 2020, 36, 654-661.	3.1	20
104	Health Service Use and Quality of Life Recovery 12 Months Following Major Osteoporotic Fracture: Latent Class Analyses of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Journal of Bone and Mineral Research, 2020, 36, 252-261.	3.1	17
105	Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study. Osteoporosis International, 2020, 31, 1079-1087.	3.3	17
106	Epidemiology of osteoporotic fracture in Moldova and development of a country-specific FRAX model. Archives of Osteoporosis, 2020, 15, 13.	2.6	20
107	The Effect of Fracture Recency on Observed 10-Year Fracture Probability: A Registry-Based Cohort Study. Journal of Bone and Mineral Research, 2020, 37, 848-855.	3.1	10
108	Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate. Journal of Bone and Mineral Research, 2020, 37, 1117-1124.	3.1	2

#	ARTICLE	IF	CITATIONS
109	Effect of Discordant Hip Bone Density on Incident Fracture Risk: A Registry-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 2018-2024.	3.1	7
110	Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. <i>Osteoporosis International</i> , 2019, 30, 2195-2203.	3.3	25
111	East meets West: current practices and policies in the management of musculoskeletal aging. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1351-1373.	3.0	34
112	FRAX-based intervention and assessment thresholds for osteoporosis in Iran. <i>Osteoporosis International</i> , 2019, 30, 2225-2230.	3.3	5
113	Influence of fall environment and fall direction on risk of injury among pre-frail and frail adults. <i>Osteoporosis International</i> , 2019, 30, 2205-2215.	3.3	14
114	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	3.3	79
115	Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. <i>Archives of Osteoporosis</i> , 2019, 14, 93.	2.6	13
116	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Oncologist</i> , 2019, 24, 1432-1438.	4.1	11
117	Temporal changes in access to FRAX® in Thailand between 2010 and 2018. <i>Archives of Osteoporosis</i> , 2019, 14, 66.	2.6	10
118	Fracture risk following intermission of osteoporosis therapy. <i>Osteoporosis International</i> , 2019, 30, 1733-1743.	3.3	42
119	Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1428-1435.	3.1	56
120	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1546-1555.	2.4	27
121	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. <i>Calcified Tissue International</i> , 2019, 105, 109-124.	3.2	55
122	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	3.0	55
123	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. <i>Calcified Tissue International</i> , 2019, 105, 1-14.	3.2	339
124	Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. <i>Calcified Tissue International</i> , 2019, 104, 235-238.	3.2	112
125	Extensive undertreatment of osteoporosis in older Swedish women. <i>Osteoporosis International</i> , 2019, 30, 1297-1305.	3.3	39
126	Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. <i>Archives of Osteoporosis</i> , 2019, 14, 15.	2.6	17

#	ARTICLE	IF	CITATIONS
127	Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporosis International, 2019, 30, 525-526.	3.3	3
128	Appendicular lean mass and fracture risk assessment: implications for FRAX® and sarcopenia. Osteoporosis International, 2019, 30, 537-539.	3.3	20
129	The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 410-417.	2.8	10
130	Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 2019, 31, 15-17.	3.0	45
131	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
132	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57.	3.3	72
133	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2019, 30, 3-44.	3.3	1,148
134	Diagnosis and Clinical Aspects of Osteoporosis. , 2019, , 11-20.		14
135	Ukrainian frax: criteria for diagnostics and treatment of osteoporosis. Bol¹, Sustavy, PozvonoÄnik, 2019, 9, 212-221.	0.1	1
136	Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS). Osteoporosis International, 2018, 29, 1147-1154.	3.3	21
137	Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures™ A Post Hoc Analysis of the SCOOP Study. Journal of Bone and Mineral Research, 2018, 33, 1020-1026.	3.1	48
138	Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. Archives of Osteoporosis, 2018, 13, 42.	2.6	16
139	Understanding osteoporotic pain and its pharmacological treatment. Osteoporosis International, 2018, 29, 1477-1491.	3.3	30
140	Bone health assessment in older people with or without muscle health impairment. Osteoporosis International, 2018, 29, 1057-1067.	3.3	39
141	Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. Osteoporosis International, 2018, 29, 751-758.	3.3	40
142	Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. Osteoporosis International, 2018, 29, 759-767.	3.3	15
143	Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 269-278.	7.5	519
144	FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporosis International, 2018, 29, 707-715.	3.3	57

#	ARTICLE	IF	CITATIONS
145	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Quality of Life Research, 2018, 27, 707-716.	3.2	38
146	Low risk for hip fracture and high risk for hip arthroplasty due to osteoarthritis among Swedish farmers. Osteoporosis International, 2018, 29, 741-749.	3.3	12
147	Does nutrition play a role in the prevention and management of sarcopenia?. Clinical Nutrition, 2018, 37, 1121-1132.	5.2	300
148	Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS. Osteoporosis International, 2018, 29, 557-566.	3.3	95
149	A health economic simulation model for the clinical management of osteoporosis. Osteoporosis International, 2018, 29, 545-555.	3.3	8
150	Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2018, 33, 510-516.	3.1	66
151	A brief history of FRAX. Archives of Osteoporosis, 2018, 13, 118.	2.6	156
152	FRAX. , 2018, , 331-339.		0
153	In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. Bone, 2018, 113, 161-168.	3.1	44
154	Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. Journal of Bone and Mineral Research, 2018, 33, 1923-1930.	3.1	116
155	Which Method of Fall Ascertainment Captures the Most Falls in Pre frail and Frail Seniors?. American Journal of Epidemiology, 2018, 187, 2243-2251.	3.7	19
156	Epidemiology of Hip Fractures in Two Regions of Ukraine. Journal of Osteoporosis, 2018, 2018, 1-6.	0.5	9
157	Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. Nutrients, 2018, 10, 555.	4.2	212
158	Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2018, 33, 2150-2157.	3.1	87
159	Benefits and safety of dietary protein for bone health—an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International, 2018, 29, 1933-1948.	3.3	104
160	<i>The Authors reply</i>: “Dual energy X-ray absorptiometry: gold standard for muscle mass?” by Scafoglieri et al.. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 788-790.	7.5	3
161	Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 2018, 29, 1505-1510.	3.3	31
162	Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). Osteoporosis International, 2018, 29, 1511-1513.	3.3	18

#	ARTICLE	IF	CITATIONS
163	Characteristics of recurrent fractures. Osteoporosis International, 2018, 29, 1747-1757.	3.3	134
164	Assessment of fracture risk. , 2018, , 163-176.		0
165	Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clinica Chimica Acta, 2017, 467, 34-41.	1.6	98
166	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 2017, 28, 767-774.	3.3	118
167	Utilisation du FRAX Â® chez lâ€™homme. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 196-198.	0.0	0
168	Imminent risk of fracture after fracture. Osteoporosis International, 2017, 28, 775-780.	3.3	310
169	Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 2017, 28, 1817-1833.	3.3	401
170	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 2017, 28, 1507-1529.	3.3	173
171	Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. JAMA Psychiatry, 2017, 74, 641.	11.6	67
172	UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 2017, 12, 43.	2.6	642
173	The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. Journal of Bone and Mineral Research, 2017, 32, 1625-1631.	3.1	42
174	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.3	130
175	FRAX for fracture prediction shorter and longer than 10Âyears: the Manitoba BMD registry. Osteoporosis International, 2017, 28, 2557-2564.	3.3	22
176	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.	2.4	52
177	Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. Journal of Bone and Mineral Research, 2017, 32, 1568-1574.	3.1	55
178	Total Hip Bone Area Affects Fracture Prediction With FRAXÂ® in Canadian White Women. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4242-4249.	3.7	8
179	Overview of Fracture Prediction Tools. Journal of Clinical Densitometry, 2017, 20, 444-450.	1.4	67
180	FRAX Update. Journal of Clinical Densitometry, 2017, 20, 360-367.	1.4	89

#	ARTICLE	IF	CITATIONS
181	FRAX- vs. T-score-based intervention thresholds for osteoporosis. <i>Osteoporosis International</i> , 2017, 28, 3099-3105.	3.3	46
182	Evaluation of clinical risk factors for osteoporosis and applicability of the FRAX tool in Joinville City, Southern Brazil. <i>Archives of Osteoporosis</i> , 2017, 12, 111.	2.6	8
183	Bisphosphonates in osteoporosis: NICE and easy?. <i>Lancet, The</i> , 2017, 390, 2243-2244.	12.2	24
184	Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate. <i>Archives of Osteoporosis</i> , 2017, 12, 98.	2.6	24
185	Epidemiology of hip fracture and the development of FRAX in Ukraine. <i>Archives of Osteoporosis</i> , 2017, 12, 53.	2.6	22
186	The role of calcium supplementation in healthy musculoskeletal ageing. <i>Osteoporosis International</i> , 2017, 28, 447-462.	3.3	141
187	How to Implement a Fracture Liaison Service. <i>Practical Issues in Geriatrics</i> , 2017, , 171-184.	0.0	0
188	Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK – an analysis of anonymous website activity. <i>Osteoporosis International</i> , 2017, 28, 71-76.	3.3	15
189	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. <i>Annals of Internal Medicine</i> , 2017, 167, 902.	9.7	2
190	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. <i>Oncotarget</i> , 2017, 8, 75646-75663.	1.8	55
191	A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. <i>Ageing Clinical and Experimental Research</i> , 2016, 28, 797-803.	3.0	110
192	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 940-948.	3.1	541
193	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. <i>European Geriatric Medicine</i> , 2016, 7, 243-246.	3.0	99
194	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. <i>European Geriatric Medicine</i> , 2016, 7, 519-525.	3.0	12
195	Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4489-4496.	3.7	96
196	A systematic review of intervention thresholds based on FRAX. <i>Archives of Osteoporosis</i> , 2016, 11, 25.	2.6	331
197	Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. <i>Archives of Osteoporosis</i> , 2016, 11, 37.	2.6	55
198	Direct comparison of FRAXR and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. <i>Osteoporosis International</i> , 2016, 27, 2689-2695.	3.3	16

#	ARTICLE	IF	CITATIONS
199	A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 647-652.	3.6	65
200	FRAX updates 2016. <i>Current Opinion in Rheumatology</i> , 2016, 28, 433-441.	4.5	38
201	Use of FRAX® in men. <i>Joint Bone Spine</i> , 2016, 83, 477-478.	1.9	4
202	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	3.0	23
203	SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. <i>Calcified Tissue International</i> , 2016, 98, 417-425.	3.2	32
204	Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. <i>Calcified Tissue International</i> , 2016, 99, 131-141.	3.2	25
205	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	3.0	126
206	FRAX predicts incident falls in elderly men: findings from MrOs Sweden. <i>Osteoporosis International</i> , 2016, 27, 267-274.	3.3	43
207	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis: From evidence-based medicine to the real-life setting. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S3-S11.	3.6	211
208	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 47-58.	3.0	94
209	Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. <i>Journal of Clinical Densitometry</i> , 2016, 19, 326-331.	1.4	48
210	Fracture risk assessment in men: the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm. <i>Journal of Clinical Densitometry</i> , 2016, 19, 332-337.	1.4	48
211	Intervention Thresholds and the Diagnosis of Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1747-1753.	3.1	108
212	Can we treat to target in osteoporosis?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 1-4.	0.3	4
213	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Endocrine</i> , 2015, 50, 12-26.	2.4	57
214	Burden of high fracture probability worldwide: secular increases 2010-2040. <i>Osteoporosis International</i> , 2015, 26, 2243-2248.	3.3	401
215	Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. <i>Osteoporosis International</i> , 2015, 26, 2793-2802.	3.3	227
216	Erratum to "The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)" [Maturitas 79 (2014) 122-132]. <i>Maturitas</i> , 2015, 80, 337.	2.6	2

#	ARTICLE	IF	CITATIONS
217	Health economic aspects of vertebral augmentation procedures. <i>Osteoporosis International</i> , 2015, 26, 1239-1249.	3.3	11
218	Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. <i>Osteoporosis International</i> , 2015, 26, 1979-1987.	3.3	77
219	Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. <i>Bone</i> , 2015, 78, 216-224.	3.1	376
220	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	3.0	31
221	FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. <i>Osteoporosis International</i> , 2015, 26, 2677-2684.	3.3	38
222	Adjusting Fracture Probability by Trabecular Bone Score. <i>Calcified Tissue International</i> , 2015, 96, 500-509.	3.2	158
223	Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. <i>Osteoporosis International</i> , 2015, 26, 2347-2353.	3.3	35
224	FRAX-based assessment and intervention thresholds – an exploration of thresholds in women aged 50 years and older in the UK. <i>Osteoporosis International</i> , 2015, 26, 2091-2099.	3.3	59
225	Is the Swedish FRAX model appropriate for Swedish immigrants?. <i>Osteoporosis International</i> , 2015, 26, 2617-2622.	3.3	35
226	FRAX and fracture prediction without bone mineral density. <i>Climacteric</i> , 2015, 18, 2-9.	1.9	61
227	Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool. <i>Osteoporosis International</i> , 2015, 26, 2573-2578.	3.3	104
228	Hip Axis Length Is a FRAX- and Bone Density-Independent Risk Factor for Hip Fracture in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2063-2070.	3.7	50
229	Incidence of hip fracture in Brazil and the development of a FRAX model. <i>Archives of Osteoporosis</i> , 2015, 10, 224.	2.6	70
230	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. <i>Pharmacoeconomics</i> , 2015, 33, 205-224.	3.5	86
231	Epidemiological Burden of Postmenopausal Osteoporosis in Italy from 2010 to 2020: Estimations from a Disease Model. <i>Calcified Tissue International</i> , 2014, 95, 419-427.	3.2	20
232	Pre-screening young postmenopausal women for BMD testing. <i>BoneKey Reports</i> , 2014, 3, 544.	2.8	2
233	The Effect of Latitude on the Risk and Seasonal Variation in Hip Fracture in Sweden. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2217-2223.	3.1	46
234	Republished: Value of biomarkers in osteoarthritis: current status and perspectives. <i>Postgraduate Medical Journal</i> , 2014, 90, 171-178.	2.0	53

#	ARTICLE	IF	CITATIONS
235	Can Change in FRAX Score Be Used to "Treat to Target"? A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1074-1080.	3.1	28
236	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	3.6	30
237	Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts. <i>Calcified Tissue International</i> , 2014, 95, 428-435.	3.2	57
238	Worldwide uptake of FRAX. <i>Archives of Osteoporosis</i> , 2014, 9, 166.	2.6	96
239	FRAX provides robust fracture prediction regardless of socioeconomic status. <i>Osteoporosis International</i> , 2014, 25, 61-69.	3.3	28
240	Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. <i>Osteoporosis International</i> , 2014, 25, 325-337.	3.3	29
241	Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. <i>Osteoporosis International</i> , 2014, 25, 235-241.	3.3	64
242	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 253-263.	3.6	424
243	Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2511-2519.	3.1	78
244	Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1356-1362.	3.1	164
245	Low holotranscobalamin and cobalamins predict incident fractures in elderly men: the MrOS Sweden. <i>Osteoporosis International</i> , 2014, 25, 131-140.	3.3	7
246	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 518-530.	3.1	646
247	The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. <i>Osteoporosis International</i> , 2014, 25, 2445-2451.	3.3	30
248	Goal-directed treatment of osteoporosis in Europe. <i>Osteoporosis International</i> , 2014, 25, 2533-2543.	3.3	63
249	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014, 79, 122-132.	2.6	230
250	Management of osteoporosis of the oldest old. <i>Osteoporosis International</i> , 2014, 25, 2507-2529.	3.3	74
251	Epidemiology and economic burden of osteoporosis in Switzerland. <i>Archives of Osteoporosis</i> , 2014, 9, 187.	2.6	82
252	Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. <i>Osteoporosis International</i> , 2014, 25, 1831-1836.	3.3	15

#	ARTICLE	IF	CITATIONS
253	Lumbar spine texture enhances 10-year fracture probability assessment. <i>Osteoporosis International</i> , 2014, 25, 2271-2277.	3.3	106
254	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. <i>Calcified Tissue International</i> , 2014, 94, 560-567.	3.2	148
255	Challenges for the Development of Bone-Forming Agents in Europe. <i>Calcified Tissue International</i> , 2014, 94, 469-473.	3.2	19
256	Consensus of Official Position of IOF/ISCD FRAX Initiatives in Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2014, 17, 150-155.	1.4	20
257	The application of health technology assessment in osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 895-910.	5.1	16
258	The Osteoporosis Treatment Gap. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1926-1928.	3.1	132
259	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 223-233.	3.1	401
260	EPIDEMIOLOGY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN FEDERATION AND THE RUSSIAN MODEL OF FRAX. <i>Osteoporosis and Bone Diseases</i> , 2014, 17, 3-8.	1.5	10
261	Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. <i>Osteoporosis International</i> , 2013, 24, 2763-2764.	3.3	130
262	Intervention thresholds for denosumab in the UK using a FRAX [®] -based cost-effectiveness analysis. <i>Osteoporosis International</i> , 2013, 24, 1491-1502.	3.3	35
263	Updated fracture incidence rates for the Italian version of FRAX [®] . <i>Osteoporosis International</i> , 2013, 24, 859-866.	3.3	33
264	Tools in the Assessment of Sarcopenia. <i>Calcified Tissue International</i> , 2013, 93, 201-210.	3.2	202
265	Health Technology Assessment in Osteoporosis. <i>Calcified Tissue International</i> , 2013, 93, 1-14.	3.2	41
266	Incidence of Hip Fracture in Barranquilla, Colombia, and the Development of a Colombian FRAX Model. <i>Calcified Tissue International</i> , 2013, 93, 15-22.	3.2	28
267	Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model. <i>Calcified Tissue International</i> , 2013, 92, 429-436.	3.2	39
268	Assessing the Impact of Osteoporosis on the Burden of Hip Fractures. <i>Calcified Tissue International</i> , 2013, 92, 42-49.	3.2	109
269	Fracture Risk Assessment. , 2013, , 1611-1637.		5
270	Quality of Life in Sarcopenia and Frailty. <i>Calcified Tissue International</i> , 2013, 93, 101-120.	3.2	323

#	ARTICLE	IF	CITATIONS
271	Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women. Archives of Osteoporosis, 2013, 8, 145.	2.6	25
272	The Resource Use Related to Hip Fractures Based on Data from ICUROS. Value in Health, 2013, 16, A573-A574.	0.3	2
273	Erratum to "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013" [Maturitas 75 (2013) 392-396]. Maturitas, 2013, 76, 387.	2.6	1
274	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2013, 43, 303-313.	3.6	249
275	FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Archives of Osteoporosis, 2013, 8, 164.	2.6	12
276	Osteoporosis in the European Union: a compendium of country-specific reports. Archives of Osteoporosis, 2013, 8, 137.	2.6	576
277	Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of Osteoporosis, 2013, 8, 136.	2.6	2,018
278	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.6	129
279	Development and application of FRAX in the management of osteoporosis in Ireland. Archives of Osteoporosis, 2013, 8, 146.	2.6	12
280	How to define responders in osteoarthritis. Current Medical Research and Opinion, 2013, 29, 719-729.	2.0	75
281	Osteoporosis risk in Type 2 diabetes patients. Expert Review of Endocrinology and Metabolism, 2013, 8, 423-425.	2.4	5
282	Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 2013, 29, 305-313.	2.0	273
283	Pitfalls in the external validation of FRAX: response to Bolland et al.. Osteoporosis International, 2013, 24, 391-392.	3.3	7
284	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2013, 24, 23-57.	3.3	1,623
285	Treatment of osteoporosis in men. Bone, 2013, 53, 134-144.	3.1	84
286	Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 2013, 75, 392-396.	2.6	269
287	Selection of Women Aged 50-64 Yr for Bone Density Measurement. Journal of Clinical Densitometry, 2013, 16, 570-578.	1.4	18
288	The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) quality of life during the first 4 months after fracture. Osteoporosis International, 2013, 24, 811-823.	3.3	118

#	ARTICLE	IF	CITATIONS
289	What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1594-1604.	7.9	91
290	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1007-1013.	3.1	28
291	FRAX updates 2012. <i>Current Opinion in Rheumatology</i> , 2012, 24, 554-560.	4.5	43
292	High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1390-1396.	3.1	50
293	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2224-2260.	12.2	9,596
294	Type 2 diabetes and bone. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2231-2237.	3.1	308
295	Cost-effective intervention thresholds against osteoporotic fractures based on FRAXÂ® in Switzerland. <i>Osteoporosis International</i> , 2012, 23, 2579-2589.	3.3	68
296	A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. <i>Osteoporosis International</i> , 2012, 23, 2507-2515.	3.3	51
297	FRAXÂ® probabilities and risk of major osteoporotic fracture in France. <i>Osteoporosis International</i> , 2012, 23, 2321-2327.	3.3	26
298	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2257-2276.	3.3	295
299	A systematic review of hip fracture incidence and probability of fracture worldwide. <i>Osteoporosis International</i> , 2012, 23, 2239-2256.	3.3	1,098
300	Variations in latitude may or may not explain the worldwide variation in hip fracture incidence. <i>Osteoporosis International</i> , 2012, 23, 2401-2402.	3.3	3
301	Treatment failure in osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2769-2774.	3.3	186
302	Fracture risk assessment. <i>Clinical Biochemistry</i> , 2012, 45, 887-893.	2.0	45
303	Antidepressant medications and osteoporosis. <i>Bone</i> , 2012, 51, 606-613.	3.1	147
304	Epidemiology of fracture in the Russian Federation and the development of a FRAX model. <i>Archives of Osteoporosis</i> , 2012, 7, 67-73.	2.6	77
305	The distribution of FRAXÂ®-based probabilities in women from Japan. <i>Journal of Bone and Mineral Metabolism</i> , 2012, 30, 700-705.	2.8	32
306	An appendix to the 2012 IOFâ€“ECTS guidelines for the management of glucocorticoid-induced osteoporosis. <i>Archives of Osteoporosis</i> , 2012, 7, 25-30.	2.6	35

#	ARTICLE	IF	CITATIONS
307	A global representation of vitamin D status in healthy populations. Archives of Osteoporosis, 2012, 7, 155-172.	2.6	266
308	Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 209-218.	2.6	16
309	The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Archives of Osteoporosis, 2012, 7, 229-235.	2.6	29
310	Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 237-246.	2.6	32
311	Management of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 2012, 91, 225-243.	3.2	79
312	Potential Extensions of the US FRAX Algorithm. Journal of Osteoporosis, 2012, 2012, 1-8.	0.5	19
313	Does osteoporosis therapy invalidate FRAX for fracture prediction?. Journal of Bone and Mineral Research, 2012, 27, 1243-1251.	3.1	110
314	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Journal of Bone and Mineral Research, 2012, 27, 1480-1486.	3.1	129
315	FRAX underestimates fracture risk in patients with diabetes. Journal of Bone and Mineral Research, 2012, 27, 301-308.	3.1	317
316	Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 2012, 28, 475-491.	2.0	40
317	Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporosis International, 2012, 23, 2063-2065.	3.3	4
318	Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis International, 2012, 23, 1839-1848.	3.3	262
319	Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcified Tissue International, 2012, 90, 365-372.	3.2	20
320	Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2012, 23, 193-199.	3.3	6
321	High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporosis International, 2012, 23, 391-397.	3.3	91
322	Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International, 2012, 23, 949-955.	3.3	133
323	The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporosis International, 2012, 23, 811-820.	3.3	86
324	Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International, 2012, 23, 75-85.	3.3	104

#	ARTICLE	IF	CITATIONS
325	A reappraisal of generic bisphosphonates in osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 213-221.	3.3	63
326	A comparative study of using non-hip bone density inputs with FRAX®. <i>Osteoporosis International</i> , 2012, 23, 853-860.	3.3	17
327	Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2012, 23, 423-431.	3.3	99
328	Calibration of FRAX® 3.1 to the Dutch population with data on the epidemiology of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 861-869.	3.3	44
329	A comparison of case-finding strategies in the UK for the management of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 907-915.	3.3	50
330	FRAX® with and without Bone Mineral Density. <i>Calcified Tissue International</i> , 2012, 90, 1-13.	3.2	180
331	FRAX - A NEW TOOL FOR THE ASSESSMENT OF FRACTURE RISK: APPLICATION IN CLINICAL PRACTICE AND THRESHOLDS FOR INTERVENTION. <i>Osteoporosis and Bone Diseases</i> , 2012, 15, 38-44.	1.5	2
332	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. <i>Journal of Clinical Densitometry</i> , 2011, 14, 171-180.	1.4	82
333	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. <i>Journal of Clinical Densitometry</i> , 2011, 14, 226-236.	1.4	47
334	FRAX® Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011, 14, 223-225.	1.4	19
335	Standardising biochemical assessment of bone turnover in osteoporosis. <i>Clinical Biochemistry</i> , 2011, 44, 1033-1034.	2.0	12
336	A FRAX® model for the assessment of fracture probability in Belgium. <i>Osteoporosis International</i> , 2011, 22, 453-461.	3.3	53
337	Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance. <i>Osteoporosis International</i> , 2011, 22, 541-549.	3.3	23
338	Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. <i>Osteoporosis International</i> , 2011, 22, 955-965.	3.3	28
339	Development and validation of a disease model for postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 771-780.	3.3	18
340	Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 967-982.	3.3	109
341	Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. <i>Osteoporosis International</i> , 2011, 22, 373-390.	3.3	223
342	Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. <i>Osteoporosis International</i> , 2011, 22, 839-847.	3.3	136

#	ARTICLE	IF	CITATIONS
343	Construction of a FRAX [®] model for the assessment of fracture probability in Canada and implications for treatment. <i>Osteoporosis International</i> , 2011, 22, 817-827.	3.3	145
344	Fracture prediction and calibration of a Canadian FRAX [®] tool: a population-based report from CaMos. <i>Osteoporosis International</i> , 2011, 22, 829-837.	3.3	164
345	A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX [®] . <i>Osteoporosis International</i> , 2011, 22, 2347-2355.	3.3	84
346	Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. <i>Osteoporosis International</i> , 2011, 22, 2359-2364.	3.3	50
347	Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. <i>Osteoporosis International</i> , 2011, 22, 391-420.	3.3	928
348	Evaluation of FRAX to characterise fracture risk in Poland. <i>Osteoporosis International</i> , 2011, 22, 2507-2512.	3.3	21
349	Guidance for the adjustment of FRAX according to the dose of glucocorticoids. <i>Osteoporosis International</i> , 2011, 22, 809-816.	3.3	264
350	Secular trends in the incidence of hip and other osteoporotic fractures. <i>Osteoporosis International</i> , 2011, 22, 1277-1288.	3.3	737
351	Towards a diagnostic and therapeutic consensus in male osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 2789-2798.	3.3	114
352	Breaking the fragility fracture cycle. <i>Osteoporosis International</i> , 2011, 22, 2049-2050.	3.3	37
353	Partial adherence: a new perspective on health economic assessment in osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 2565-2573.	3.3	56
354	Interpretation and use of FRAX in clinical practice. <i>Osteoporosis International</i> , 2011, 22, 2395-2411.	3.3	463
355	Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2011, 89, 91-104.	3.2	176
356	Osteoporosis: burden, health care provision and opportunities in the EU. <i>Archives of Osteoporosis</i> , 2011, 6, 59-155.	2.6	472
357	Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. <i>Archives of Osteoporosis</i> , 2011, 6, 179-188.	2.6	69
358	Milk intake and risk of hip fracture in men and women: A meta-analysis of prospective cohort studies. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 833-839.	3.1	121
359	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1271-1274.	2.4	288
360	Recommendations for bone marker standards in osteoporosis: what, why and where to now?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 91-92.	1.6	8

#	ARTICLE	IF	CITATIONS
361	The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. Polish Archives of Internal Medicine, 2011, 121, 148-155.	0.5	8
362	Smoking predicts incident fractures in elderly men: Mr OS Sweden. Journal of Bone and Mineral Research, 2010, 25, 1010-1016.	3.1	60
363	Validation of the IOF quality of life questionnaire for patients with wrist fracture. Osteoporosis International, 2010, 21, 61-70.	3.3	21
364	The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporosis International, 2010, 21, 339-349.	3.3	23
365	FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporosis International, 2010, 21, 381-389.	3.3	109
366	The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®. Osteoporosis International, 2010, 21, 495-505.	3.3	46
367	The effects of a FRAX® revision for the USA. Osteoporosis International, 2010, 21, 35-40.	3.3	91
368	The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporosis International, 2010, 21, 41-52.	3.3	99
369	Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporosis International, 2010, 21, 53-60.	3.3	62
370	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2010, 21, 713-722.	3.3	10
371	Development and use of FRAX® in osteoporosis. Osteoporosis International, 2010, 21, 407-413.	3.3	334
372	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis, 2010, 5, 19-48.	2.6	18
373	Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. Journal of Bone and Mineral Research, 2010, 25, 2350-2358.	3.1	250
374	New osteoporosis guidelines for Canada. Cmaj, 2010, 182, 1829-1830.	4.2	12
375	FRAX® and its applications in health economics – Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone, 2010, 47, 430-437.	3.1	35
376	A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®. Bone, 2010, 47, 729-735.	3.1	94
377	Diagnostic Thresholds for Osteoporosis in Men. , 2010, , 605-611.		3
378	Cost-Effectiveness of Hormone Therapy in the United States. Journal of Women's Health, 2009, 18, 1669-1677.	3.4	26

#	ARTICLE	IF	CITATIONS
379	Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. <i>Menopause International</i> , 2009, 15, 19-25.	1.5	13
380	How to decide who to treat. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 711-726.	3.6	23
381	From relative risk to absolute fracture risk calculation: The FRAX algorithm. <i>Current Osteoporosis Reports</i> , 2009, 7, 77-83.	3.7	132
382	Incorporating adherence into health economic modelling of osteoporosis. <i>Osteoporosis International</i> , 2009, 20, 23-34.	3.3	63
383	Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. <i>Osteoporosis International</i> , 2009, 20, 1131-1140.	3.3	177
384	Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. <i>Osteoporosis International</i> , 2009, 20, 811-817.	3.3	135
385	The incidence and risk of hip fracture in Poland. <i>Osteoporosis International</i> , 2009, 20, 1363-1367.	3.3	41
386	An updated systematic review of Health State Utility Values for osteoporosis related conditions. <i>Osteoporosis International</i> , 2009, 20, 853-868.	3.3	118
387	BMD, clinical risk factors and their combination for hip fracture prevention. <i>Osteoporosis International</i> , 2009, 20, 1675-1682.	3.3	122
388	Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores. <i>Osteoporosis International</i> , 2009, 20, 1939-1945.	3.3	44
389	Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. <i>Osteoporosis International</i> , 2009, 20, 2055-2061.	3.3	34
390	Assessment of fracture risk. <i>European Journal of Radiology</i> , 2009, 71, 392-397.	2.8	113
391	FRAX® and its applications to clinical practice. <i>Bone</i> , 2009, 44, 734-743.	3.1	618
392	Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. <i>Bone</i> , 2009, 44, 1049-1054.	3.1	150
393	Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. <i>Maturitas</i> , 2009, 62, 105-108.	2.6	348
394	Approaches to the targeting of treatment for osteoporosis. <i>Nature Reviews Rheumatology</i> , 2009, 5, 425-431.	8.2	39
395	The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. <i>Osteoporosis International</i> , 2008, 19, 819-827.	3.3	18
396	Expressing fracture risk. <i>Osteoporosis International</i> , 2008, 19, 593-594.	3.3	3

#	ARTICLE	IF	CITATIONS
397	FRAX [®] and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 2008, 19, 385-397.	3.3	2,071
398	Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX [®]). Osteoporosis International, 2008, 19, 429-435.	3.3	164
399	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2008, 19, 399-428.	3.3	804
400	NICE continues to muddy the waters of osteoporosis. Osteoporosis International, 2008, 19, 1105-1107.	3.3	4
401	Case finding for the management of osteoporosis with FRAX [®] assessment and intervention thresholds for the UK. Osteoporosis International, 2008, 19, 1395-1408.	3.3	526
402	Assessment of the 10-Year Probability of Osteoporotic Hip Fracture Combining Clinical Risk Factors and Heel Bone Ultrasound: The EPSEM Prospective Cohort of 12,958 Elderly Women. Journal of Bone and Mineral Research, 2008, 23, 1045-1051.	3.1	67
403	Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis. Journal of Bone and Mineral Research, 2008, 23, 1561-1568.	3.1	90
404	Health economics of osteoporosis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 885-900.	5.1	26
405	Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK – Results based on the Women's Health Initiative randomised controlled trial. Bone, 2008, 42, 294-306.	3.1	31
406	The cost-effectiveness of alendronate in the management of osteoporosis. Bone, 2008, 42, 4-15.	3.1	140
407	A reference standard for the description of osteoporosis. Bone, 2008, 42, 467-475.	3.1	966
408	Modelling cost-effectiveness in osteoporosis. Bone, 2008, 43, 215-216.	3.1	5
409	Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone, 2008, 43, 343-347.	3.1	58
410	Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair. Journal of Bone and Joint Surgery - Series A, 2008, 90, 43-47.	3.0	20
411	FRAX [®] and the assessment of fracture probability: An introduction. IBMS BoneKEy, 2008, 5, 114-117.	0.1	0
412	The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks. Value in Health, 2007, 10, 348-357.	0.3	28
413	Cost-effectiveness of the treatment and prevention of osteoporosis – a review of the literature and a reference model. Osteoporosis International, 2007, 18, 9-23.	3.3	171
414	The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis International, 2007, 18, 1033-1046.	3.3	1,044

#	ARTICLE	IF	CITATIONS
415	Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporosis International, 2007, 18, 1047-1061.	3.3	93
416	Adherence to treatment of osteoporosis: a need for study. Osteoporosis International, 2007, 18, 1311-1317.	3.3	103
417	Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, 2007, 11, iii-iv, ix-xi, 1-231.	3.0	124
418	Olof Johnell. Journal of Clinical Densitometry, 2006, 9, 387.	1.4	0
419	The hospitalisation costs and out-patient costs of fragility fractures. Women's Health Medicine, 2006, 3, 149-151.	0.0	36
420	Preservation of thoracic spine microarchitecture by alendronate: Comparison of histology and microCT. Bone, 2006, 38, 444-449.	3.1	25
421	Cost Implications of Bisphosphonates. , 2006, , 415-426.		0
422	Prevention of Bone Loss. , 2006, , 399-414.		0
423	Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study. Journal of Bone and Mineral Research, 2006, 22, 135-141.	3.1	182
424	The use of multiple sites for the diagnosis of osteoporosis. Osteoporosis International, 2006, 17, 527-534.	3.3	92
425	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2006, 17, 1369-1381.	3.3	34
426	The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporosis International, 2006, 17, 996-1007.	3.3	55
427	At what hip fracture risk is it cost-effective to treat?. Osteoporosis International, 2006, 17, 1459-1471.	3.3	117
428	Bone fragility in men - where are we?. Osteoporosis International, 2006, 17, 1577-1583.	3.3	97
429	An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis International, 2006, 17, 1726-1733.	3.3	3,692
430	An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting. Osteoporosis International, 2006, 17, 1781-1793.	3.3	66
431	A simple clinical score for estimating the long-term risk of fracture in post-menopausal women. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 673-682.	0.5	43
432	Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. Journal of the Operational Research Society, 2005, 56, 214-221.	3.4	22

#	ARTICLE	IF	CITATIONS
433	Predictive Value of BMD for Hip and Other Fractures. Journal of Bone and Mineral Research, 2005, 20, 1185-1194.	3.1	1,233
434	Potential Impact of Osteoporosis Treatment on Hip Fracture Trends. Journal of Bone and Mineral Research, 2005, 20, 895-897.	3.1	36
435	Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporosis International, 2005, 16, 6-14.	3.3	110
436	Smoking and fracture risk: a meta-analysis. Osteoporosis International, 2005, 16, 155-162.	3.3	777
437	The burden of hospitalised fractures in Sweden. Osteoporosis International, 2005, 16, 222-228.	3.3	92
438	Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis International, 2005, 16, 15-25.	3.3	65
439	The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporosis International, 2005, 16, 313-318.	3.3	116
440	Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporosis International, 2005, 16, 475-482.	3.3	92
441	Alcohol intake as a risk factor for fracture. Osteoporosis International, 2005, 16, 737-742.	3.3	490
442	A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporosis International, 2005, 16, 799-804.	3.3	123
443	Assessment of fracture risk. Osteoporosis International, 2005, 16, 581-589.	3.3	1,085
444	Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography. Osteoporosis International, 2005, 16, 1065-1070.	3.3	37
445	Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis International, 2005, 16, 229-238.	3.3	401
446	The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporosis International, 2005, 16, 456-459.	3.3	28
447	Body mass index as a predictor of fracture risk: A meta-analysis. Osteoporosis International, 2005, 16, 1330-1338.	3.3	1,327
448	Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. Osteoporosis International, 2005, 16, 2025-2030.	3.3	72
449	The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry. Journal of Clinical Densitometry, 2005, 8, 145-147.	1.4	20
450	Intervention thresholds for osteoporosis in the UK. Bone, 2005, 36, 22-32.	3.1	113

#	ARTICLE	IF	CITATIONS
451	Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 728-736.	3.1	115
452	A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 893-899.	3.1	681
453	Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 764-772.	3.1	106
454	Risk Factors for Incident Vertebral Fractures in Men and Women: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1172-1180.	3.1	161
455	Evidence From Data Searches and Life-Table Analyses for Gender-Related Differences in Absolute Risk of Hip Fracture After Colles' or Spine Fracture: Colles' Fracture as an Early and Sensitive Marker of Skeletal Fragility in White Men. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1933-1944.	3.1	88
456	Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 906-913.	3.1	132
457	The risk and burden of vertebral fractures in Sweden. <i>Osteoporosis International</i> , 2004, 15, 20-26.	3.3	222
458	Mortality after osteoporotic fractures. <i>Osteoporosis International</i> , 2004, 15, 38-42.	3.3	721
459	Fracture risk following an osteoporotic fracture. <i>Osteoporosis International</i> , 2004, 15, 175-179.	3.3	384
460	Excess mortality after hospitalisation for vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 108-112.	3.3	255
461	Health-related quality of life and radiographic vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 113-119.	3.3	163
462	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. <i>Osteoporosis International</i> , 2004, 15, 760-765.	3.3	107
463	An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. <i>Osteoporosis International</i> , 2004, 15, 897-902.	3.3	768
464	Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. <i>Osteoporosis International</i> , 2004, 15, 862-871.	3.3	77
465	Epidemiology of Osteoporosis and Fracture in Men. <i>Calcified Tissue International</i> , 2004, 75, 90-99.	3.2	84
466	Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden. <i>Pharmacoeconomics</i> , 2004, 22, 1153-1165.	3.5	46
467	Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. <i>Bone</i> , 2004, 34, 728-735.	3.1	165
468	A meta-analysis of previous fracture and subsequent fracture risk. <i>Bone</i> , 2004, 35, 375-382.	3.1	1,085

#	ARTICLE	IF	CITATIONS
469	A family history of fracture and fracture risk: a meta-analysis. <i>Bone</i> , 2004, 35, 1029-1037.	3.1	349
470	Study Design in Osteoporosis: A European Perspective. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1133-1138.	3.1	19
471	Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1254-1260.	3.1	224
472	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2003, 14, 19-26.	3.3	252
473	Cost-equivalence of different osteoporotic fractures. <i>Osteoporosis International</i> , 2003, 14, 383-388.	3.3	169
474	The components of excess mortality after hip fracture. <i>Bone</i> , 2003, 32, 468-473.	3.1	470
475	Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial ¹¹ Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.. <i>Bone</i> , 2003, 33, 293-300.	3.1	169
476	Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). <i>Bone</i> , 2003, 33, 505-513.	3.1	194
477	Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density. <i>Postgraduate Medical Journal</i> , 2003, 79, 581-584.	2.0	7
478	Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3219-3224.	5.3	364
479	Diagnosis of osteoporosis and assessment of fracture risk. <i>Lancet, The</i> , 2002, 359, 1929-1936.	12.2	1,817
480	Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. <i>Bone</i> , 2002, 30, 251-258.	3.1	181
481	Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment. <i>Bone</i> , 2002, 30, 754-758.	3.1	9
482	Calcitonin in osteoporosis. <i>Bone</i> , 2002, 30, 65-66.	3.1	7
483	Intervention thresholds for osteoporosis. <i>Bone</i> , 2002, 31, 26-31.	3.1	76
484	Falls explain between-center differences in the incidence of limb fracture across Europe. <i>Bone</i> , 2002, 31, 712-717.	3.1	47
485	Uncertain Future of Trials in Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 443-449.	3.3	45
486	Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability. <i>Osteoporosis International</i> , 2002, 13, 523-526.	3.3	183

#	ARTICLE	IF	CITATIONS
487	A New Approach to the Development of Assessment Guidelines for Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 527-536.	3.3	297
488	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2002, 13, 565-571.	3.3	191
489	Economic Evaluation of Interventions for Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 765-767.	3.3	51
490	A Systematic Review of Health State Utility Values for Osteoporosis-Related Conditions. <i>Osteoporosis International</i> , 2002, 13, 768-776.	3.3	95
491	Defining Incident Vertebral Deformities in Population Studies: A Comparison of Morphometric Criteria. <i>Osteoporosis International</i> , 2002, 13, 809-815.	3.3	42
492	Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 841-857.	3.3	56
493	Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS). <i>Journal of Bone and Mineral Research</i> , 2002, 17, 716-724.	3.1	561
494	International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1237-1244.	3.1	514
495	Neurological Complications of Paget's Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 135-144.	0.8	11
496	Treatment of established osteoporosis: a systematic review and cost-utility analysis. <i>Health Technology Assessment</i> , 2002, 6, 1-146.	3.0	198
497	The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma. <i>Drugs</i> , 2001, 61, 1253-1274.	11.2	36
498	Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. <i>Bone</i> , 2001, 28, 310-315.	3.1	47
499	Targeting of hormone replacement therapy immediately after menopause. <i>Bone</i> , 2001, 28, 440-445.	3.1	10
500	Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds. <i>Osteoporosis International</i> , 2001, 12, 989-995.	3.3	725
501	Cost-Effectiveness of Preventing Hip Fracture in the General Female Population. <i>Osteoporosis International</i> , 2001, 12, 356-361.	3.3	59
502	The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds. <i>Osteoporosis International</i> , 2001, 12, 417-427.	3.3	610
503	Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture. <i>Osteoporosis International</i> , 2001, 12, 207-214.	3.3	129
504	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2001, 12, 85-90.	3.3	159

#	ARTICLE	IF	CITATIONS
505	Diagnosis of Osteoporosis and Fracture Threshold in Men. <i>Calcified Tissue International</i> , 2001, 69, 218-221.	3.2	79
506	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. <i>Calcified Tissue International</i> , 2001, 68, 348-351.	3.2	36
507	Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 1035-1043.	2.8	160
508	Une maladie osseuse de Paget familiale atypique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2001, 68, 439-444.	0.0	0
509	Atypical familial Paget's disease of bone. <i>Joint Bone Spine</i> , 2001, 68, 257-261.	1.9	4
510	Bisphosphonates in multiple myeloma. <i>Cancer</i> , 2000, 88, 3022-3032.	4.1	46
511	Insufficiency fracture of the calcaneum: an unusual cause of heel pain. <i>Foot</i> , 2000, 10, 169-171.	1.1	1
512	An update on the diagnosis of osteoporosis. <i>Current Rheumatology Reports</i> , 2000, 2, 62-66.	5.0	39
513	An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry. <i>Osteoporosis International</i> , 2000, 11, 192-202.	3.3	808
514	Metacarpal Morphometry Using a Semi-automated Technique in the Assessment of Osteoporosis and Vertebral Fracture Risk. <i>Osteoporosis International</i> , 2000, 11, 953-958.	3.3	26
515	Long-Term Risk of Osteoporotic Fracture in Malmö. <i>Osteoporosis International</i> , 2000, 11, 669-674.	3.3	829
516	Is a Calculated Total Hip BMD of Clinical Use?. <i>Osteoporosis International</i> , 2000, 11, 368-371.	3.3	7
517	Risk of Hip Fracture Derived from Relative Risks: An Analysis Applied to the Population of Sweden. <i>Osteoporosis International</i> , 2000, 11, 120-127.	3.3	113
518	Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. <i>Maturitas</i> , 2000, 37, 75-81.	2.6	40
519	Prediction of fracture from low bone mineral density measurements overestimates risk. <i>Bone</i> , 2000, 26, 387-391.	3.1	53
520	Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. <i>Bone</i> , 2000, 26, 525-528.	3.1	15
521	Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: II. three-dimensional histology. <i>Bone</i> , 2000, 27, 277-282.	3.1	109
522	Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. two-dimensional histology. <i>Bone</i> , 2000, 27, 271-276.	3.1	105

#	ARTICLE	IF	CITATIONS
523	Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. <i>Bone</i> , 2000, 27, 585-590.	3.1	363
524	Comparison of the European and USA Practice Guidelines for Osteoporosis. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 28-32.	7.2	42
525	Effect of calcitonin on vertebral and other fractures. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1999, 92, 143-150.	0.5	50
526	Osteoporosis: Who, When, How Long to Treat, and with What Effectiveness?. <i>Drug Information Journal</i> , 1999, 33, 315-319.	0.5	0
527	Economic impact of using clodronate in the management of patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999, 104, 358-364.	2.8	40
528	A high incidence of vertebral fracture in women with breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 1179-1181.	6.6	245
529	Clinical Assessment of Bone Mass, Quality and Architecture. <i>Osteoporosis International</i> , 1999, 9, S24-S28.	3.3	13
530	Number and Type of Vertebral Deformities: Epidemiological Characteristics and Relation to Back Pain and Height Loss. <i>Osteoporosis International</i> , 1999, 9, 206-213.	3.3	258
531	Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). <i>Osteoporosis International</i> , 1999, 10, 150-160.	3.3	352
532	The burden of osteoporosis. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 583-588.	3.5	68
533	Circumstances around the fall in a multinational hip fracture risk study: a diverse pattern for prevention. <i>Accident Analysis and Prevention</i> , 1998, 30, 607-616.	5.8	36
534	Short-term Reproducibility of Proximal Femur Bone Mineral Density in the Elderly. <i>Calcified Tissue International</i> , 1998, 63, 296-299.	3.2	27
535	Lifetime Risk of Hip Fractures is Underestimated. <i>Osteoporosis International</i> , 1998, 8, 599-603.	3.3	153
536	A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 317-325.	2.8	292
537	Risk factors in osteoporosis. <i>Maturitas</i> , 1998, 30, 229-233.	2.6	55
538	Advances in osteoporosis. <i>Lancet</i> , The, 1998, 351, 379.	12.2	5
539	Biochemical markers in osteoporosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 6-11.	1.2	8
540	Alendronate in the treatment of Paget's disease of bone. <i>Bone</i> , 1997, 20, 263-271.	3.1	44

#	ARTICLE	IF	CITATIONS
541	Osteoporosis: a view into the next century. Netherlands Journal of Medicine, 1997, 50, 198-203.	0.7	9
542	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 1997, 12, 1700-1707.	3.1	249
543	Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study. Journal of Bone and Mineral Research, 1997, 12, 1883-1894.	3.1	177
544	Preliminary study on relationship between vertebral fracture and aortic calcification in postmenopausal women. Journal of Bone and Mineral Metabolism, 1997, 15, 218-222.	2.8	3
545	World-wide Projections for Hip Fracture. Osteoporosis International, 1997, 7, 407-413.	3.3	1,770
546	Vitamin D analogs: From renal bone disease to osteoporosis. Calcified Tissue International, 1997, 60, 106-110.	3.2	4
547	Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European foundation for osteoporosis. Osteoporosis International, 1997, 7, 36-38.	3.3	168
548	The hospital burden of vertebral fracture in Europe: A study of national register sources. Osteoporosis International, 1997, 7, 138-141.	3.3	84
549	Guidelines for diagnosis and management of osteoporosis. Osteoporosis International, 1997, 7, 390-406.	3.3	721
550	Bone density measurements and osteoporosis. Journal of Internal Medicine, 1997, 241, 173-175.	6.2	6
551	Bone turnover and biochemical markers in malignancy. Cancer, 1997, 80, 1538-1545.	4.1	63
552	Clodronate. Cancer, 1997, 80, 1691-1695.	4.1	15
553	Bone turnover and biochemical markers in malignancy. Cancer, 1997, 80, 1538-1545.	4.1	16
554	Clodronate. Cancer, 1997, 80, 1691-1695.	4.1	5
555	Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone, 1996, 19, 663-667.	3.1	219
556	Duration of response with oral clodronate in Paget's disease of bone. Bone, 1996, 18, 185-190.	3.1	160
557	Paget's disease of bone and unvaccinated dogs. Bone, 1996, 19, 47-50.	3.1	46
558	Evaluation of the risk of hip fracture. Bone, 1996, 18, S127-S132.	3.1	57

#	ARTICLE	IF	CITATIONS
559	The interpretation and utility of ultrasound measurements of bone. <i>Bone</i> , 1996, 18, 491-492.	3.1	30
560	8 The menopause and the skeleton: key issues. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1996, 10, 469-481.	0.7	3
561	The GREES Recommendations for the Registration of New Drugs in the Prevention and Treatment of Osteoporosis. <i>Calcified Tissue International</i> , 1996, 59, 410-411.	3.2	0
562	Effect of pulsed electromagnetic fields on bone formation and bone loss during limb lengthening. <i>Bone</i> , 1996, 18, 505-509.	3.1	99
563	Rationale for the Use of Bisphosphonates in Breast Cancer. <i>Acta Oncol³gica</i> , 1996, 35, 61-67.	1.9	14
564	Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the european foundation for osteoporosis and bone disease. <i>Osteoporosis International</i> , 1996, 6, 256-261.	3.3	80
565	Medroxyprogesterone and bone mineral density response to oestrogen. <i>Clinical Endocrinology</i> , 1996, 44, 297-298.	2.7	0
566	Influence of Life Style in the MEDOS Study. <i>Scandinavian Journal of Rheumatology</i> , 1996, 25, 112-112.	1.2	12
567	A Mental-functional Risk Score for Prediction of Hip Fracture. <i>Age and Ageing</i> , 1996, 25, 439-442.	1.7	19
568	Comparison of three intravenous regimens of clodronate in paget disease of bone. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 178-182.	3.1	26
569	The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 1010-1018.	3.1	794
570	Estrogens, the menopause, and osteoporosis. <i>Bone</i> , 1996, 19, S185-S190.	3.1	56
571	A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. <i>British Journal of Cancer</i> , 1995, 72, 1289-1293.	6.6	153
572	The use of alfacalcidol in the prevention of bone disease in early renal failure. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 23-28.	0.8	2
573	Rationale for the use of alendronate in osteoporosis. <i>Osteoporosis International</i> , 1995, 5, 1-13.	3.3	73
574	Influence of age and body mass on the effects of vitamin d on hip fracture risk. <i>Osteoporosis International</i> , 1995, 5, 450-454.	3.3	25
575	Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. <i>Calcified Tissue International</i> , 1995, 56, 109-112.	3.2	18
576	Sustained response to intravenous alendronate in postmenopausal osteoporosis. <i>Bone</i> , 1995, 17, 517-520.	3.1	32

#	ARTICLE	IF	CITATIONS
577	How to assess drug efficacy in osteoporosis. <i>Lancet</i> , The, 1995, 345, 743-744.	12.2	12
578	Perspectives assessment of involutinal bone loss: Methodological and conceptual problems. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 511-517.	3.1	46
579	The effects of intravenous alendronate in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1094-1100.	3.1	27
580	Risk factors for hip fracture in european women: The MEDOS study. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1802-1815.	3.1	475
581	Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. <i>BMJ: British Medical Journal</i> , 1995, 310, 358-363.	5.7	281
582	Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis?. <i>Nephrology Dialysis Transplantation</i> , 1994, 9, 511-516.	0.8	30
583	ALGODYSTROPHY: AN UNDER-RECOGNIZED COMPLICATION OF MINOR TRAUMA. <i>Rheumatology</i> , 1994, 33, 240-248.	2.1	157
584	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. <i>Osteoporosis International</i> , 1994, 4, 368-381.	3.3	1,939
585	The variable incidence of hip fracture in Southern Europe: The MEDOS study. <i>Osteoporosis International</i> , 1994, 4, 253-263.	3.3	266
586	Bone loss in the elderly. <i>Osteoporosis International</i> , 1994, 4, S59-S65.	3.3	47
587	Treatment of Paget's disease—An overview. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 23, 254-255.	3.6	4
588	Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease. <i>Seminars in Arthritis and Rheumatism</i> , 1994, 23, 271.	3.6	4
589	The effect of alendronate on renal tubular reabsorption of phosphate. <i>Bone and Mineral</i> , 1994, 27, 51-56.	1.9	7
590	An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. <i>Bone and Mineral</i> , 1994, 24, 127-134.	1.9	55
591	Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. <i>Bone</i> , 1994, 15, 161-166.	3.1	171
592	Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment. <i>Clinical Drug Investigation</i> , 1994, 7, 26-33.	2.3	16
593	Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). <i>British Journal of Cancer</i> , 1994, 69, 914-917.	6.6	30
594	The diagnosis of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 1137-1141.	3.1	3,091

#	ARTICLE	IF	CITATIONS
595	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. <i>British Journal of Cancer</i> , 1993, 67, 560-563.	6.6	77
596	The assessment of vertebral deformity: A method for use in population studies and clinical trials. <i>Osteoporosis International</i> , 1993, 3, 138-147.	3.3	506
597	Therapeutic strategies in the prevention of hip fracture with drugs affecting bone metabolism. <i>Bone</i> , 1993, 14, 85-87.	3.1	22
598	What Constitutes Evidence for Drug Efficacy in Osteoporosis?. <i>Drugs and Aging</i> , 1993, 3, 391-399.	3.0	20
599	Differentiation of heterogeneous phenotypes in human osteoblastt cultures in response to 1,25-dihydroxyvitamin D3. <i>Bone</i> , 1993, 14, 763-767.	3.1	12
600	Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The chingford study. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 817-822.	3.1	124
601	Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1124-1128.	5.7	264
602	Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate). <i>Drug Safety</i> , 1992, 7, 162-165.	3.3	27
603	Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis. <i>Bone and Mineral</i> , 1992, 17, 399-413.	1.9	19
604	Intravenous alendronate therapy in post-menopausal osteoporosis. <i>Bone and Mineral</i> , 1992, 17, S25.	1.9	2
605	Osteoporotic fractures: An unusual presentation of haemochromatosis. <i>Bone</i> , 1992, 13, 431-433.	3.1	41
606	Epidemiology of vertebral osteoporosis. <i>Bone</i> , 1992, 13, S1-S10.	3.1	130
607	The apparent incidence of hip fracture in Europe: A study of national register sources. <i>Osteoporosis International</i> , 1992, 2, 298-302.	3.3	350
608	Quality of life and vertebral osteoporosis. <i>Osteoporosis International</i> , 1992, 2, 161-163.	3.3	49
609	An automated method for the analysis of trabecular bone structure. <i>Journal of Biomedical Informatics</i> , 1992, 25, 1-16.	0.7	35
610	Paleohistology of Paget's disease in two medieval skeletons. <i>American Journal of Physical Anthropology</i> , 1992, 89, 325-331.	2.1	32
611	Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. <i>European Journal of Haematology</i> , 1992, 49, 192-198.	2.3	172
612	Effects of five daily 1 h infusions of alendronate in paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 81-87.	3.1	33

#	ARTICLE	IF	CITATIONS
613	The effect of sodium fluoride on trabecular architecture. <i>Bone</i> , 1991, 12, 307-310.	3.1	39
614	Familial expansile osteolysis: A morphological, histomorphometric and serological study. <i>Bone</i> , 1991, 12, 331-338.	3.1	47
615	Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. <i>Bone</i> , 1991, 12, 17-20.	3.1	29
616	1,25(OH)2D3 induces differentiation of osteoclast-like cells from human bone marrow cultures. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 1189-1195.	2.2	27
617	Immunoreactivity and proliferative actions of \hat{I}^{22} microglobulin on human bone-derived cells in vitro. <i>Biochemical and Biophysical Research Communications</i> , 1991, 175, 795-803.	2.2	27
618	A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. <i>Arthritis and Rheumatism</i> , 1991, 34, 287-295.	7.0	74
619	Guidelines for clinical trials in Osteoporosis. <i>Osteoporosis International</i> , 1991, 1, 182-188.	3.3	52
620	Actions of calcipotriol (MC 903), a novel vitamin D3 analog, on human bone-derived cells: Comparison with 1,25-dihydroxyvitamin D3. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 1307-1315.	3.1	20
621	Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 483-491.	3.1	69
622	Bone loss and age-related fractures. <i>Experimental Gerontology</i> , 1990, 25, 289-296.	2.9	11
623	Increased potency of 1,25-dihydroxyvitamin D3 on human osteoblast-like cells following structural side-chain modification. <i>Bone</i> , 1990, 11, 439-443.	3.1	5
624	Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin. <i>Journal of Hepatology</i> , 1990, 11, 354-358.	4.0	39
625	1,25(OH)2D3 and calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 1056-1063.	2.2	18
626	Involvement of prostaglandin E2 in the inhibition of osteocalcin synthesis by human osteoblast-like cells in response to cytokines and systemic hormones. <i>Biochemical and Biophysical Research Communications</i> , 1990, 167, 194-202.	2.2	44
627	Vitamin D metabolism in myeloma. <i>British Journal of Haematology</i> , 1989, 73, 57-60.	2.8	12
628	Indices of calcium metabolism in women with hip fractures. <i>Bone and Mineral</i> , 1989, 5, 193-200.	1.9	44
629	Fatal Cardiac Zygomycosis in a Renal Transplant Patient Treated with Desferrioxamine. <i>Nephrology Dialysis Transplantation</i> , 1989, 4, 911-913.	0.8	20
630	Calcium supplementation of the diet-II.. <i>BMJ: British Medical Journal</i> , 1989, 298, 205-208.	5.7	89

#	ARTICLE	IF	CITATIONS
631	Calcium supplementation of the diet-I.. BMJ: British Medical Journal, 1989, 298, 137-140.	5.7	126
632	Calcium metabolism and myeloma and the treatment of hypercalcemia. Hematological Oncology, 1988, 6, 115-117.	1.8	1
633	8 Renal osteodystrophy. Bailliere's Clinical Endocrinology and Metabolism, 1988, 2, 193-241.	0.9	11
634	Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone, 1988, 9, 123-130.	3.1	115
635	Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy. Clinica Chimica Acta, 1987, 164, 285-291.	1.6	15
636	Paramyxovirus-like inclusions in two cases of pycnodysostosis. Bone, 1987, 8, 211-217.	3.1	42
637	Osteopenia in systemic mastocytosis: Natural history and responses to treatment with inhibitors of bone resorption. Bone, 1987, 8, 149-155.	3.1	56
638	REMISSION OF HYPOPARATHYROIDISM DURING LACTATION: EVIDENCE FOR A PHYSIOLOGICAL ROLE FOR PROLACTIN IN THE REGULATION OF VITAMIN D METABOLISM. Clinical Endocrinology, 1987, 26, 667-674.	2.7	43
639	Aminohexane diphosphonate in the treatment of paget' s disease of bone. Journal of Bone and Mineral Research, 1987, 2, 273-279.	3.1	43
640	Thallium-pertechnetate subtraction scintigraphy: A quantitative comparison between adenomatous and hyperplastic parathyroid glands. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 12, 31-36.	6.7	18
641	Treatment of malignant hypercalcaemia with clodronate. British Journal of Cancer, 1985, 51, 665-669.	6.6	50
642	Deflazacortâ€”a safer systemic steroid for the treatment of chronic dermatoses. British Journal of Dermatology, 1985, 113, 34-35.	1.7	4
643	ABNORMAL VITAMIN D METABOLISM IN PAGET'S DISEASE OF BONE. Clinical Endocrinology, 1985, 22, 559-566.	2.7	11
644	LONGâ€”TERM EFFECTS OF HISTAMINE H²â€”RECEPTOR ANTAGONISTS ON SERUM PARATHYROID HORMONE IN CHRONIC RENAL FAILURE. Clinical Endocrinology, 1985, 23, 277-282.	2.7	5
645	Assessment of thallium-pertechnetate subtraction scintigraphy in hyperparathyroidism. British Journal of Radiology, 1985, 58, 131-135.	2.2	17
646	The mechanism of hypocalcaemia following thyroidectomy. European Journal of Endocrinology, 1985, 109, 220-226.	4.1	41
647	Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption.. Postgraduate Medical Journal, 1985, 61, 551-553.	2.0	18
648	Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone. Bone, 1985, 6, 69-72.	3.1	3

#	ARTICLE	IF	CITATIONS
649	Monitoring the treatment of paget's disease with etidronate. <i>Calcified Tissue International</i> , 1984, 36, 629-631.	3.2	18
650	Calcium Metabolism in Osteogenesis Imperfecta. <i>Clinical Science</i> , 1984, 67, 21P-22P.	4.4	0
651	Intravenous Clodronate in the Treatment and Retreatment of Paget's Disease. <i>Clinical Science</i> , 1984, 67, 40P-41P.	4.4	0
652	Aminohexane Diphosphonate (AHDP) for the Treatment of Paget's Disease. <i>Clinical Science</i> , 1984, 67, 73P-74P.	4.4	1
653	The Use of Ethane-1-Hydroxy-1,1-Diphosphonate (EHDP) in the Management of Hormone-Resistant Prostatic Carcinoma. <i>Clinical Science</i> , 1984, 67, 74P-74P.	4.4	0
654	Plasma hydroxyproline in uremia: Relationships with histologic and biochemical indices of bone turnover. <i>Metabolic Bone Disease & Related Research</i> , 1983, 4, 297-303.	0.5	13
655	The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. <i>British Journal of Haematology</i> , 1983, 54, 121-132.	2.8	86
656	THE USE OF DIPHOSPHONATES IN MYELOMA. <i>British Journal of Haematology</i> , 1983, 53, 688-690.	2.8	1
657	SERUM ALUMINIUM MEASUREMENTS IN RENAL BONE DISEASE. <i>Lancet, The</i> , 1983, 321, 1168-1169.	12.2	14
658	Calcium Metabolism in Subjects Living with a Permanent Ileostomy. <i>Digestion</i> , 1983, 26, 131-136.	2.5	3
659	Vitamin A and hyperparathyroid bone disease in uremia. <i>American Journal of Clinical Nutrition</i> , 1983, 38, 914-920.	4.7	11
660	Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol. <i>European Journal of Endocrinology</i> , 1982, 101, 636-640.	4.1	14
661	1,25(OH) ₂ D ₃ Binding Protein from Normal Pig Intestine: Characterisation and its Use in the Assay of Serum 1,25(OH) ₂ D ₃ Concentrations. <i>Clinical Science</i> , 1982, 62, 56P-57P.	4.4	0
662	DETERIORATION OF RENAL BONE DISEASE IN PATIENTS TREATED WITH SALMON CALCITONIN. <i>Clinical Endocrinology</i> , 1982, 16, 29-37.	2.7	14
663	The Diagnostic and Aetiological Significance of Certain Ultrastructural Features of the Osteoclasts in Paget's Disease of Bone. <i>Clinical Science</i> , 1981, 60, 11P-11P.	4.4	1
664	Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover. <i>European Journal of Clinical Investigation</i> , 1981, 11, 177-184.	3.5	10
665	Lack of clinical and physiological relationship between gastrin and calcitonin in man. <i>European Journal of Clinical Investigation</i> , 1981, 11, 331-335.	3.5	12
666	Effects of 24,25-dihydroxy-vitamin D ₃ on its plasma level in man. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 155-158.	0.5	9

#	ARTICLE	IF	CITATIONS
667	Diphosphonates and paget's disease of bone. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 217.	0.5	2
668	Paget's bloom of bone : Diagnosis and management. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 219-230.	0.5	13
669	Biochemical markers of bone turnover in paget's disease. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 255-262.	0.5	36
670	Paget's disease: Improvment of spinal cord dysfunction with diphosphonates and Calcitonin. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 327-335.	0.5	20
671	The role of vitamin D metabolites in the osteomalacia of renal disease. <i>Current Medical Research and Opinion</i> , 1981, 7, 294-315.	2.0	10
672	Comparison of acute effects of 1.25- and 24.25-dihydroxy-vitamin D3 in normal subjects. <i>European Journal of Endocrinology</i> , 1981, 98, 619-624.	4.1	6
673	The pathophysiology of hypercaemia. <i>Metabolic Bone Disease & Related Research</i> , 1980, 2, 151-159.	0.5	23
674	Physiology and pharmacological regulation of bone resorption. <i>Metabolic Bone Disease & Related Research</i> , 1980, 2, 177-189.	0.5	20
675	An Evaluation of 1a-Hydroxy-and 1,25-Dihydroxyvitamin D3 in the Treatment of Renal Bone Disease. <i>Contributions To Nephrology</i> , 1980, 18, 12-28.	0.0	9
676	ETHANOLINDUCED SECRETION OF CALCITONIN IN CHRONIC RENAL DISEASE. <i>Clinical Endocrinology</i> , 1979, 10, 155-161.	2.7	11
677	The biological effects of 1, 24, 25-Trihydroxyvitamin D3 in man. <i>Metabolic Bone Disease & Related Research</i> , 1979, 1, 295-298.	0.5	7
678	The Absence of 24,25-Dihydroxycholecalciferol in Anephric Patients. <i>Clinical Science and Molecular Medicine</i> , 1978, 55, 541-547.	0.6	22
679	Evidence for a Direct Effect of 24,25-Dihydroxycholecalciferol on Intestinal Absorption of Calcium. <i>Clinical Science and Molecular Medicine</i> , 1978, 54, 23P-24P.	0.6	0
680	La Calcitonine Serique Dans La Cirrhose Ethylique. <i>Acta Clinica Belgica</i> , 1978, 33, 296-302.	1.2	0
681	Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.. <i>Archives of Disease in Childhood</i> , 1977, 52, 473-481.	2.8	34
682	Changes in Histologic and Biochemical Indexes of Bone Turnover after Bilateral Nephrectomy in Patients on Hemodialysis. <i>New England Journal of Medicine</i> , 1977, 296, 1073-1079.	30.7	53
683	Plasma Calcitonin in Paget's Disease of Bone. <i>Clinical Science and Molecular Medicine</i> , 1977, 52, 329-332.	0.6	12
684	Osteomalacia associated with increased renal tubular resorption of phosphate (hypohyperparathyroidism). <i>Postgraduate Medical Journal</i> , 1976, 52, 295-297.	2.0	8

#	ARTICLE	IF	CITATIONS
685	Mixed sclerosing bone dystrophy with regression of melorheostosis. British Journal of Radiology, 1975, 48, 400-402.	2.2	20
686	An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in paget's disease. Clinica Chimica Acta, 1975, 63, 227-229.	1.6	41
687	The use of anticoagulants in bacterial endocarditis. Postgraduate Medical Journal, 1974, 50, 312-313.	2.0	26
688	SERIAL ASSAYS OF PLASMA GROWTH HORMONE IN TREATED AND UNTREATED ACROMEGALY. Journal of Endocrinology, 1974, 63, 21-34.	2.7	18
689	FRAX [®] : Assessment of Fracture Risk. , 0, , 289-296.		2
690	IOF position on scientists and societies operating in conflict zones. Osteoporosis International, 0, , .	3.3	0
691	Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk. Osteoporosis International, 0, , .	3.3	0